Antibody phage display technologies with special reference to angiogenesis.
AffiliationUniversity of Manchester, Stopford Building, Oxford Rd, Manchester, M13 9PT, UK. Jusmith@fs1.scg.man.ac.uk
MetadataShow full item record
AbstractThe presence of blood vessels is a prerequisite for normal development, tissue growth, and tissue repair. However, its abnormal occurrence or absence can also potentiate disease processes. Angiogenic therapies have been used to stimulate blood vessel growth in ischemic conditions such as severe end-stage peripheral vascular disease, ischemic heart disease and stroke and for inhibition of angiogenesis in tumors. The targeting and identification of novel endothelial cell (EC) markers that can ultimately be used in angiogenic strategies is an expanding field but is limited by the availability of reagents. For instance repeated injection of mouse monoclonal antibodies (Mabs) against angiogenic EC, can result in the production of autoantibodies. Therefore, these mouse Mabs cannot be used for therapeutic purposes. Phage display technology was employed in this context to select antibodies, proteins, and peptides against known or novel EC antigens. Furthermore, technologies have been developed that enable the specific targeting of epitopes on cells including the endothelium with high-affinity/avidity antibodies. The focus for these antibody targeting strategies are markers that are unique or up-regulated on angiogenic EC including the vascular endothelial growth factor receptor (VEGFR) KDR, endoglin (CD105), and the extracellular domain B (ED-B) domain of fibronectin (FN). These markers are reviewed herein.
CitationAntibody phage display technologies with special reference to angiogenesis. 2005, 19 (3):331-41 FASEB J.
JournalThe FASEB Journal
- Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
- Authors: Takahashi N, Haba A, Matsuno F, Seon BK
- Issue date: 2001 Nov 1
- Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105).
- Authors: Nettelbeck DM, Miller DW, Jérôme V, Zuzarte M, Watkins SJ, Hawkins RE, Müller R, Kontermann RE
- Issue date: 2001 Jun
- Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
- Authors: Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M
- Issue date: 1997 Jul
- Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.
- Authors: She X, Matsuno F, Harada N, Tsai H, Seon BK
- Issue date: 2004 Jan 10
- Production and characterization of a high-affinity nanobody against human endoglin.
- Authors: Ahmadvand D, Rasaee MJ, Rahbarizadeh F, Mohammadi M
- Issue date: 2008 Oct